Previous close | 71.60 |
Open | 71.60 |
Bid | 71.75 |
Ask | 75.90 |
Strike | 200.00 |
Expiry date | 2024-05-17 |
Day's range | 71.60 - 71.60 |
Contract range | N/A |
Volume | |
Open interest | N/A |
(Bloomberg) -- Investors who may have missed out on the blistering rally in Eli Lilly & Co. and Novo Nordisk A/S are once again taking a chance with Amgen Inc.Most Read from BloombergTruce Talks Drag as Hamas Hits Israel Crossing in Deadly AttackBuffett Praises Apple After Trimming It, Drops Paramount StakeFrance’s Macron Calls for Reset of Economic Ties With ChinaTreasury Rally Risks Running Into a $125 Billion Brick WallXi Begins Europe Tour in Paris as Macron Seeks to Reset TiesThe shares sur
Competition is heating up in the GLP-1 space as Amgen gets closer to the finish line with its candidate.
Novo Nordisk A/S (NYSE:NVO) Q1 2024 Earnings Call Transcript May 2, 2024 Novo Nordisk A/S misses on earnings expectations. Reported EPS is $0.7 EPS, expectations were $0.77. NVO isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good day! And thank […]